Bimatoprost promotes satiety and attenuates body weight gain in rats fed standard or obesity-promoting diets. (December 2022)

• Record Type: Journal Article
• Authors: Spada, Clayton; Vu, Chau; Raymond, Iona; Tong, Warren; Chuang, Chia-Lin; Walker, Christopher; Loomes, Kerry; Woodward, David F.; Poloso, Neil J.
• Is Part Of: Prostaglandins, leukotrienes, and essential fatty acids. Volume 187(2022)
• Publication Date: 2022-12
• Subjects: Obesity -- Satiety -- Anandamide -- Bimatoprost -- Prostamide; Lipids -- Periodicals; Unsaturated fatty acids -- Periodicals; Prostaglandins -- Periodicals; Leukotrienes -- Periodicals; Fatty Acids, Unsaturated -- Periodicals; Acides gras insaturés -- Périodiques; Prostaglandines -- Périodiques; Leucotriènes -- Périodiques; Lipides -- Périodiques; 612.01577
• DOI: 10.1016/j.plefa.2022.102511
• Languages: English
• ISSNs: 0952-3278

Abstract

Highlights: Skin administration of bimatoprost led to a dose dependent reduction in weight gain. Application led to reduction of fat under the skin and systemically. Systemic effect mediated by a decrease in food intake and gastric emptying. Extends previously published findings of bimatoprost and prostamides on adiposity. Abstract: Bimatoprost is a synthetic prostamide F2α analog that down-regulates adipogenesis in vitro. This effect has been attributed to participation in a negative feedback loop that regulates anandamide-induced adipogenesis. A follow-on investigation has now been conducted into the broader metabolic effects of bimatoprost using rats under both normal state and obesity-inducing conditions. Chronic bimatoprost administration attenuated weight gain in a dose dependent-manner in rats fed either standard [max effect −7%] or obesity-promoting diets [max effect −23%] over a 9–10 week period. Consistent with these findings, bimatoprost promoted satiety as measured by decreased food intake [max effect, −7%], gastric emptying [max effect, −33–50%] and decreased circulating concentrations of the gut hormones, ghrelin and GLP-1 [max effect, −33–50%]. Additionally, subcutaneous, and visceral fat mass were distinctly affected by treatment [−30% diet independent]. Taken together, these results suggest that bimatoprost regulates energy homeostasis through promoting satiety and a decrease in food intake. These newly reported activities of bimatoprost reveal an additional method of metabolic disease intervention for potential therapeutic exploitation.